ロード中...
Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease
Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in ap...
保存先:
| 出版年: | Future Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6331693/ https://ncbi.nlm.nih.gov/pubmed/30105925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2018-0215 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|